The coronavirus pandemic has affected many industries and economies around the world, in addition to affecting global physical health, with continuous disconnection and social isolation aggravating the mental health crisis further. It has also emphasized the need to find new ways to improve the treatment of mental health conditions, with one recent study reporting that ketamine held the potential to become an effective treatment for depression when administered during the pandemic.
Ketamine is mainly used as an anesthetic but has also demonstrated that it can be used to treat depression. The study, which was reported in the “Psychiatry Research” journal, compared the efficaciousness of four IV ketamine treatments that were administered to two groups. The two groups comprised of the control group, which included 160 patients who had received the ketamine treatment a year before the coronavirus pandemic began, and the latter group, made up of 107 patients who received the infusions between March 2020 and February 2021. Patients in both groups suffered from treatment-resistant depression.
The researchers discovered little variation in the reduction of symptoms between the pair of groups, noting that the patients in the control group showed similar improvements in their symptoms as those who had received the ketamine treatment prior to the pandemic. They added that the improvements were significant and rapid in both groups, which established the efficaciousness of ketamine treatment for patients that need it. The researchers’ discovery also shows the strong antidepressant effects of ketamine therapy in an extremely stressful time, such as the coronavirus lockdown period.
As the virus spread, governments across the globe imposed lockdowns in an attempt to contain the spread, which resulted in increased levels of anxiety, loneliness and social isolation. While the researchers were skeptical that the downsides of the pandemic would disrupt ketamine’s antidepressant effects, the opposite was observed.
In their study, the researchers explain that they observed major improvements in the mental health of patients who received the treatment during the pandemic, which demonstrates the potent effects that ketamine treatment holds. They assert that their findings are important, especially when one considers that patients who suffer from severe mental health conditions have a higher risk of experiencing worse outcomes of the coronavirus if they do contract it, in addition to being more susceptible to contracting the infection.
The researchers note that the use of ketamine in treating depression may be a new way to reduce the physical impact of contracting COVID-19.
Ketamine, DMT and other psychedelic substances have shown so much therapeutic potential that several companies, including XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), have invested heavily in developing medicines from those substances in order to treat some of the most hard-to-treat variations of mental health conditions.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
